Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein-47 and collagen type i in rat hepatic stellate cells in vitro

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 309-314

  Xiang, Xian Hong ^a   Jiang, Tian Peng ^b   Zhang, Shuai ^b   Song, Jie ^b   Li, Xing ^b   Yang, Jian Yong ^a   Zhou, Shi ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cell division; Collagen type I; Heat shock protein 47; Hepatic stellate cells; Liver fibrosis; Pirfenidone

Indexed keywords

COLLAGEN TYPE 1; HEAT SHOCK PROTEIN 47; MESSENGER RNA; PIRFENIDONE; RNA 18S; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; RAT;

RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN TYPE I; DOWN-REGULATION; G1 PHASE CELL CYCLE CHECKPOINTS; HEPATIC STELLATE CELLS; HSP47 HEAT-SHOCK PROTEINS; PYRIDONES; RATS; RNA, MESSENGER;

EID: 84926643376     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3403     Document Type: Article

References (38)

1. Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250, 2000.
2. Milani S, Herbst H, Schuppan D, Surrenti C, Riecken EO and Stein H: Cellular localization of type I III and IV procollagen gene transcripts in normal and fibrotic human liver. Am J Pathol 137: 59-70, 1990.
3. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005.
4. Taguchi T and Razzaque MS: The collagen-specific molecular chaperone HSP47: Is there a role in fibrosis. Trends Mol Med 13: 45-53, 2007.
5. Razzaque MS, Le VT and Taguchi T: Heat shock protein 47 and renal fibrogenesis. Contrib Nephrol 148: 57-69, 2005.
6. Chen JJ, Jin PS, Zhao S, Cen Y, Liu Y, Xu XW, Duan WQ and Wang HS: Effect of heat shock protein 47 on collagen synthesis of keloid in vivo. ANZ J Surg 81: 425-430, 2011.
7. Brown KE, Broadhurst KA, Mathahs MM, Brunt EM and Schmidt WN: Expression of HSP47, a collagen-specific chaperone, in normal and diseased human liver. Lab Invest 85: 789-797, 2005.
8. Nakayama S, Mukae H, Sakamoto N, et al: Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts. Life Sci 82: 210-217, 2008.
9. Sato Y, Murase K, Kato J, et al: Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 26: 431-442, 2008.
10. Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, Oku H, Miyazaki M, Kadota J and Kohno S: Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 24: 57-65, 2004.
11. Zhao XY, Zeng X, Li XM, Wang TL and Wang BE: Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol 36: 963-968, 2009.
12. Armendáriz-Borunda J, Rincón AR, Muñoz-Valle JF, et al: Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. J Investig Med 56: 944-953, 2008.
13. Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB and Becker GJ: Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14: 453-460, 2001.
14. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM and Brown L: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133: 687-694, 2001.
15. Sun G, Lin X, Zhong H, Yang Y, Qiu X, Ye C, Wu K and Yu M: Pharmacokinetics of pirfenidone after topical administration in rabbit eye. Mol Vis 17: 2191-2196, 2011.
16. Lin X, Yu M, Wu K, Yuan H and Zhong H: Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 50: 3763-3770, 2009.
17. Di Sario A, Bendia E, Svegliati Baroni G, et al: Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 37: 584-591, 2002.
18. Gurujeyalakshmi G, Hollinger MA and Giri SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 276: L311-L318, 1999.
19. Grattendick KJ, Nakashima JM, Feng L, Giri SN and Margolin SB: Effects of three anti-TNF-alpha drugs: Etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol 8: 679-687, 2008.
20. Oku H, Nakazato H, Horikawa T, Tsuruta Y and Suzuki R: Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 446: 167-176, 2002.
21. Ginès P, Cárdenas A, Arroyo V and Rodés J: Management of cirrhosis and ascites. N Engl J Med 350: 1646-1654, 2004.
22. Rockey DC: Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 12: 939-962, xi, 2008.
23. Zhao W, Li JJ, Cao DY, Li X, Zhang LY, He Y, Yue SQ, Wang DS and Dou KF: Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol 18: 1048-1058, 2012.
24. Behr J: Idiopathic pulmonary fibrosis: Modern guideline-concordant diagnostics and innovative treatment. Dtsch Med Wochenschr 137: 601-604, 2012 (In German).
25. Salazar-Montes A, Ruiz-Corro L, López-Reyes A, Castrejón-Gómez E and Armendáriz-Borunda J: Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 595: 69-77, 2008.
26. Di Sario A, Bendia E, Macarri G, Candelaresi C, Taffetani S, Marzioni M, Omenetti A, De Minicis S, Trozzi L and Benedetti A: The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 36: 744-751, 2004.
27. Tada S, Nakamuta M, Enjoji M, Sugimoto R, Iwamoto H, Kato M, Nakashima Y and Nawata H: Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 28: 522-527, 2001.
28. Navarro-Partida J, Martinez-Rizo AB, Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V and Armendariz-Borunda J: Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmacol 678: 71-77, 2012.
29. Sauk JJ, Nikitakis N and Siavash H: Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target. Front Biosci 10: 107-118, 2005.
30. Taguchi T, Nazneen A, Al-Shihri AA, Turkistani KA and Razzaque MS: Heat shock protein 47: A novel biomarker of phenotypically altered collagen-producing cells. Acta Histochem Cytochem 44: 35-41, 2011.
31. Nagata K: Therapeutic strategy for fibrotic diseases by regulating the expression of collagen-specific molecular chaperone HSP47. Nippon Yakurigaku Zasshi 121: 4-14, 2003 (In Japanese).
32. Xia Z, Abe K, Furusu A, Miyazaki M, Obata Y, Tabata Y, Koji T and Kohno S: Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47. Am J Nephrol 28: 34-46, 2008.
33. Hagiwara S, Iwasaka H, Shingu C, Matumoto S, Hasegawa A and Noguchi T: Heat shock protein 47 (HSP47) antisense oligonucleotides reduce cardiac remodeling and improve cardiac function in a rat model of myocardial infarction. Thorac Cardiovasc Surg 59: 386-392, 2011.
34. Dams SD, de Liefde-van Beest M, Nuijs AM, Oomens CW and Baaijens FP: Heat shocks enhance procollagen type I and III expression in fibroblasts in ex vivo human skin. Skin Res Technol 17: 167-180, 2011.
35. Sauk JJ, Smith T, Norris K and Ferreira L: Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(I) chains of type I procollagen. J Biol Chem 269: 3941-3946, 1994.
36. Sunamoto M, Kuze K, Tsuji H, Ohishi N, Yagi K, Nagata K, Kita T and Doi T: Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress collagen accumulation in experimental glomerulonephritis. Lab Invest 78: 967-972, 1998.
37. Hagiwara S, Nakamura K, Hamada H, et al: Inhibition of type I procollagen production by tRNAVal CTE-HSP47 ribozyme. J Gene Med 5: 784-794, 2003.
38. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, Ozono Y, Koji T and Kohno S: Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 64: 887-896, 2003.